EWTX Trading Analysis - 10/28/2026 02:30 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of Edgewise Therapeutics (EWTX) and are separated from the data-driven analysis below:

• EWTX announced positive topline results from a Phase 2 trial in_duchenne muscular dystrophy earlier in 2026, reinforcing pipeline focus.
• The company presented at a major biotech conference in October 2026, highlighting upcoming catalytic clinical readouts.
• Recent secondary offering rumors caused intermittent volatility in small-cap biotech peers, though no EWTX-specific confirmation.
• No near-term earnings date was flagged in general knowledge; fiscal year end per data is 2025-12-01 with no ex-dividend events.
• Context: Headlines suggest pipeline optimism, which may partially explain the bullish options flow seen in embedded data, but technicals remain non-directional.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for EWTX:

• Trailing P/E is listed at 3.70, but trailing EPS is -1.85 (negative), indicating the P/E is non-meaningful for profitability assessment.
• Forward P/E, PEG ratio, price-to-book, total revenue, revenue growth, profit margins, ROE, and debt-to-equity are all null or not provided.
• Market cap is $4,332,213,560.00 with 108,604,000.00 shares outstanding; dividend yield is 0.00% (no dividend).
• Beta is 0.49 (low relative market volatility); 52-week high $48.51, low $15.66; institutional ownership 40.61%.
• Historical volatility is 46.02%; average volume 1,406,000.00 shares.
• Analyst consensus and target price are null (no numberOfAnalystOpinions or targetMeanPrice).
• Fundamentals show negative earnings with limited disclosed metrics; this diverges from the bullish options sentiment and neutral technicals, suggesting speculation rather than fundamental support.

Current Market Position

From the embedded data: Current price per indicators is $39.58 (as of 2026-10-27). Minute bars show 2026-10-27 open $39.51, low $39.14, close $39.20 early; by 2026-10-28 14:00 close $40.07 with volume 35,162. Daily history: 2026-10-27 close $39.58, high $40.33, low $39.03, volume 421,840 (below 20-day avg 799,210).

Intraday momentum: Price rose from $39.20 (2026-10-27 09:30) to $40.07 (2026-10-28 14:00), a gradual uptick with low-volume consolidation mid-session (e.g., 208 vol at 09:40) then spike at final bar.

Technical Analysis

SMA trends: SMA 5 (39.49) > SMA 20 (39.18) but both below SMA 50 (41.66) – no golden cross; price below 50-day confirms bearish intermediate structure. RSI 48.97 is neutral, no momentum extreme. MACD line -0.67 below signal -0.54, histogram -0.13 negative – mild bearish momentum. Bollinger: middle 39.18, upper 41.66, lower 36.70; price 39.58 near middle, no squeeze (range normal). 30-day high 48.51, low 35.63; price at ~30% of range ((39.58-35.63)/(48.51-35.63)=30.3%), lower-middle.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only): Call dollar vol $560.00, Put $0.00, total $560.00, call pct 100.00%, sentiment Bullish. Only 1 contract qualified (filter ratio 0.3% of 348). Conviction shows pure directional call buying but extremely thin sample. Near-term expectation: minor bullish skew, but divergence from neutral technicals (MACD neg, price < SMA50) noted in spread advice "Wait for alignment".

Call Volume: $560.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $560.00

Key Price Levels (observational only)